Status:
COMPLETED
Identifying Potential Effects of Liraglutide on Degenerative Changes
Lead Sponsor:
University of Aarhus
Conditions:
Alzheimers Disease
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice. The investigators hypothesis is that a 6-month treatment wi...
Detailed Description
The incidences of both type 2 diabetes (DM-2) and Alzheimer's disease (AD) have increased during the last years, resulting in an increase in morbidity and mortality. DM-2 is a risk factor for both AD ...
Eligibility Criteria
Inclusion
- Informed consent before study-related activity
- Adult competent persons
- Diagnosed with diagnosed Alzheimer's disease. With a MMSE score between 18-21 the diagnosis should be entirely based on the clinic, while diagnosis by MMSE with a score \> 22 should be diagnosed by spinal puncture
- Age ≥ 50 years and ≤ 80 years
- Caucasians
Exclusion
- Diabetes mellitus
- Clinically significant liver (s-ALT \> 2 times upper reference or creatinine-clearance \< 30 mL / min, assessed on Cockcroft-Gault normogram)
- Clinically significant anemia
- Other clinically relevant abnormal biochemical value
- Current or former presence of one of the following diseases with clinical relevance:
- another CNS-illness other than diagnosed depression treated with SSRI or SSRI similar drugs.
- liver disease
- kidney disease
- endocrinological disease other than well controlled hypothyroidism
- Current or history of chronic or acute pancreatitis
- Any disease which the investigators believe may affect the study
- Patients treated with TCA or neuroleptics
- Known abuse of alcohol or drugs
- Known allergy to liraglutide or any of the other components (disodium phosphate dihydrate, propylene glycol and phenol)
- Participation in a clinical trial less than 3 months before inclusion in this study
- Persons who within a period of the last 2 years have participated in scientific experiments involving the use of isotopes, or who have had greater diagnostic tests performed using applied ionizing radiation
- If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable
- Claustrophobia or other missing cooperation
- Severe overweight \> 130kg
- Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body
- Significant abnormities in the brain detected by MR scanning
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT01469351
Start Date
January 1 2012
End Date
April 1 2013
Last Update
April 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University
Aarhus, Denmark, 8000